PuSH - Publication Server of Helmholtz Zentrum München

Palma, M.* ; Chaufan, M.* ; Breuer, C.B.* ; Müller, S.* ; Sabatier, M.* ; Fraser, C.S.* ; Szylo, K.J.* ; Yavari, M.* ; Carmona, A.* ; Kaur, M.* ; Melo, L.M.N.* ; Cansiz, F.* ; Monge-Lorenzo, J.* ; Flores, M.A.E.* ; Mishima, E. ; Nakamura, T. ; Proneth, B. ; Labrado, M.* ; Liang, Y.* ; Cayting, N.* ; Zheng, L.* ; Cañeque, T.* ; Colombeau, L.* ; Wahida, A. ; Friedmann Angeli, J.P.* ; Tasdogan, A.* ; Hui, S.T.* ; Rodriguez, R.* ; Conrad, M. ; Reticker-Flynn, N.E.* ; Ubellacker, J.M.*

Lymph node environment drives FSP1 targetability in metastasizing melanoma.

Nature, DOI: 10.1038/s41586-025-09709-1 (2025)
Publ. Version/Full Text Research data DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Ferroptosis has emerged as an actionable target to eliminate therapy-resistant and metastatic cancers1. However, which ferroptosis surveillance systems may offer a therapeutic window to leverage redox maladaptation in cancer remains unclear. In melanoma, glutathione peroxidase 4 (GPX4) impedes ferroptosis during haematogenous metastasis, but is dispensable during lymphatic metastasis2. Here, using a metastatic mouse melanoma model selected for lymph node metastasis, we show that lymph-node-derived metastatic cells exhibit markedly diminished expression of glutamate-cysteine ligase (GCLC) and reduced glutathione (GSH) levels relative to their parental counterparts. This metabolic shift occurs within the hypoxic lymphatic niche. Under comparable low-oxygen conditions, GPX4 undergoes ubiquitination and proteasomal degradation. In response, lymph node metastatic cells acquire increased reliance on ferroptosis suppressor protein 1 (FSP1), which is localized with perinuclear lysosomes. These findings reveal that the reduced reliance on the GPX4 axis enables melanoma cells to shift toward FSP1 dependency. Notably, intratumoural monotherapy with selective FSP1 inhibitors (viFSP1 and FSEN1) effectively suppresses melanoma growth in lymph nodes, but not in subcutaneous tumours, emphasizing a microenvironment-specific dependency on FSP1. Thus, targeting FSP1 in the lymph nodes holds strong potential for blocking melanoma progression.
Impact Factor
Scopus SNIP
Altmetric
48.500
0.000
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Scientific Article
Language english
Publication Year 2025
HGF-reported in Year 2025
ISSN (print) / ISBN 0028-0836
e-ISSN 1476-4687
Journal Nature
Publisher Nature Publishing Group
Publishing Place London
Reviewing status Peer reviewed
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Genetics and Epidemiology
PSP Element(s) G-506900-001
PubMed ID 41193799
Erfassungsdatum 2025-11-07